β‐ TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1
Molecular Oncology · 2026
DOI: 10.1002/1878-0261.70089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Rocío Jiménez-Guerrero und 8 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain. Hauptthemen laut MEDLINE: Cisplatin, BRCA1 Protein, beta-Transducin Repeat-Containing Proteins, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Co-funded by FEDER from Regional Development European Funds (European Union), Instituto de Salud Carlos III, Consejería de Salud y Familias, Junta de Andalucía, Spain.
Abstract (Originalsprache)
Cisplatin is one of the most used anticancer chemotherapy agents; however, over time, patients develop resistance to the treatment, and survival rates drop dramatically. Investigation of tumor cell resistance mechanisms could increase sensitivity and prevent cancer progression. Here, we investigated the role of the E3 ubiquitin ligase SCF (β‐TrCP) in cisplatin resistance in different tumor cell lines, analyzing its role in the stability of BRCA1 and CtIP, proteins involved in DNA damage repair by homologous recombination. We showed that SCF(β‐TrCP) plays a key role in cisplatin response, as overexpression of wild‐type β‐TrCP increased DNA damage and cisplatin‐induced apoptosis, while overexpression of a dominant‐negative mutant or siRNA‐mediated downregulation of β‐TrCP decreased the damage and conferred treatment resistance. Furthermore, we demonstrated that BRCA1 and CtIP interacted with β‐TrCP in vivo , and their levels changed when β‐TrCP expression was modulated. We also described that β‐TrCP‐mediated BRCA1 degradation involves both lysosomal and proteasomal pathways. Mechanistically, the failure of β‐TrCP to regulate the degradation of BRCA1 enables a more efficient DNA damage repair and thereby the acquisition of cisplatin resistance. Overall, β‐TrCP overexpression sensitizes cisplatin‐induced DNA damage by depleting BRCA1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain.
- Department of Microbiology, Faculty of Biology, Universidad de Sevilla, Spain.
- Department of Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain.
- Department of Pathology, Hospital Universitario Virgen del Rocío, Seville, Spain.
ORCID-Profile: Carmen Sáez, Miguel Á Japón
Förderung
- Co-funded by FEDER from Regional Development European Funds (European Union)
- Instituto de Salud Carlos III
- Consejería de Salud y Familias, Junta de Andalucía, Spain
- Ministerio de Ciencia, Innovación y Universidades
- European Commission
Zitieren
APA
Jiménez-Guerrero, R., Belmonte-Fernández, A., González-Moreno, M., Rodríguez-Cordero, L., Pérez-Valderrama, B., Herrero-Ruíz, J., Romero, F., Sáez, C., & Japón, M. Á. (2026). β‐ TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1. Molecular Oncology. https://doi.org/10.1002/1878-0261.70089
Vancouver
Jiménez-Guerrero R, Belmonte-Fernández A, González-Moreno M, Rodríguez-Cordero L, Pérez-Valderrama B, Herrero-Ruíz J, et al. β‐ TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1. Molecular Oncology. 2026. doi:10.1002/1878-0261.70089
BibTeX
@article{JimnezGuerrero2026,
author = {Jiménez-Guerrero, Rocío and Belmonte-Fernández, Alejandro and González-Moreno, Mónica and Rodríguez-Cordero, Laura and Pérez-Valderrama, Begoña and Herrero-Ruíz, Joaquín and Romero, Francisco and Sáez, Carmen and Japón, Miguel Á},
title = {β‐ TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1},
journal = {Molecular Oncology},
year = {2026},
doi = {10.1002/1878-0261.70089}
}
EUVIMED